The Shrinking Discovery Deal Market
Executive Summary
Since 1998, the number of deals between European biotechs and pharmas of all geographies has been shrinking steadily. These numbers shrank even as investors poured money into increasing numbers of biotechs, almost all of them based on a partnering model which was rapidly losing its logical basis.